Hexima : CEO's Presentation

12/01/2021 | 05:51pm EST

For personal use only

HEXIMA LIMITED

ASX ANNOUNCEMENT

02 November 2021

2021 ANNUAL GENERAL MEETING - CEO'S PRESENTATION

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) provides the attached CEO Presentation to be delivered at today's Annual General Meeting commencing at 11.00am AEDT.

The AGM can be joined at https://meetings.linkgroup.com/HXL21

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO.

Enquiries:

Dr Nicole van der Weerden Chief Operating Officer n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please click here

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on Twitterand LinkedInor email us at info@hexima.com.au.

LEVEL 4 LIMS 2, KINGSBURY DRIVE, LA TROBE UNIVERSITY VIC 3086

ersonal use only

MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER PRESENTATION

MR MICHAEL ALDRIDGE

MAJOR ACHIEVEMENTS FY2021

onlyMilestones & Achievements
•	Public Offering and listing on ASX
use	o $3 million offering at A$0.20 per share

•	Phase IIb clinical trial
ersonal	o Initiation and completion of enrolment
Intellectual property protection
•
•	Scientific Advisory Board
	o Australian, US and Japan KOLs

CompliancePak

AGM 2021

S L I D E 3

12 WEEK DAILY DOSING FOLLOWED

BY ONCE WEEKLY DOSING

ONCE-WEEKLYDOSING

WEEK

A U S T R A L I A N P H A S E I I B C L I N I C A L T R I A L

HXP124-ONY-002

Enrolment completed

only 12 WEEK

DAILY DOSING use

31 WEEK

DAILY DOSING

ersonalDAILY DOSING NOTE: DAILY DOSING PERIODS INCLUDE 1-WEEKWASHOUTS EVERY 6 WEEKS

HXP124-ONY-002 ANZCTR registration number: ACTRN12620000697987

WEEK	WEEK	WEEK
24	36	40

NO DOSING	FOLLOW-UP VISITS
WASHOUT PERIOD

AGM 2021

July 2021

Multi-center,randomised, double blind, vehicle-controlled study
Primary endpoint safety and tolerability, secondary endpoints Mycological Cure and Clinical Efficacy
Three active (2% pezadeftide) versus vehicle arms to test optimal dosing strategy
Safety & efficacy assessed at 13, 24, 36 and 40 weeks, data expected Q2 2022

SLID 4

S t r o n g p a t e n t p o s i t i o n

ADDITIONAL PROTECTION VIA FORMULATION PATENTS AND MARKET

only
EXCLUSIVITY FOR BIOLOGICS
Clearly defined
use
growth strategy
•	Develop independently in
	US and EU (ICH) markets
•	License and collaborative
ersonal

development in Japan and potentially China - presently in preliminary discussions with multiple parties

Granted patents	Granted and	12-year US market
(exp 2035) in major	pending patents	exclusivity on FDA
markets covering the	covering stabilising	approval likely available
use of pezadeftide in	formulation for	as a biologic drug
the treatment of	pezadeftide
onychomycosis

AGM 2021

SLIDE 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Disclaimer

Hexima Limited published this content on 01 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2021 22:50:05 UTC.

HEXIMA LIMITED

Hexima : CEO's Presentation

Send by mail :